Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

2014 SNMMI Annual Meeting

June 7-11, 2014St. Louis, MO 

Thumbnail

AAN: Super Bowl hero receives award for advocating awareness of TBI

Today the American Academy of Neurology (AAN) will be presenting a leadership in neurology award to Ben Utecht, a National Football League champion who suffered a traumatic brain injury (TBI) that tackled his career in 2009.

Genetic testing developed to end era of brain disorder in Turkey

Advanced gene sequencing has found a single genetic mutation essential for a brain disorder that has been plaguing Turkish families for centuries.

Incretin receptor imaging: A new option for NETs

In the first trial of its kind, a new type of peptide receptor is being targeted in neuroendocrine tumor (NET) imaging, which could reveal previously hidden cancer, according to a study published April 17 in the Journal of Nuclear Medicine.

Thumbnail

AAN: DaTscan SPECT on display for diagnosis of dopamine disorders

Data from multiple clinical trials for DaTscan (I-123 FP-CIT Ioflupane) using SPECT shows that the exam is very sensitive for detecting striatal dopaminergic deficits, according to a presentation during the American Academy of Neurology being held April 26 through May 3 in Philadelphia.

Vizamyl distribution to begin within a few months

The first markets for newly FDA-approved Vizamyl (F-18 flutemetamol), designated for ruling out Alzheimer’s disease and other dementias, were announced during the annual meeting of the American Academy of Neurology this week in Philadelphia, according to a statement from its producer, GE Healthcare.

A-synuclein drug therapy in the pipeline for Alzheimer’s, Parkinson’s

A potential therapy targeting the misfolded proteins in neurodegenerative disease including Alzheimer;s, Parkinson’s and Huntington’s disease is edging closer to human trials, NeuroPhage Pharmaceuticals announced April 22.

European consortium to develop Parkinson’s vaccine

A therapeutic vaccine for Parkinson’s disease and multiple system atrophy (MSA) is the primary objective of a group of leading research teams across Europe, Austrian pharmaceutical company Affiris announced April 28.